177 related articles for article (PubMed ID: 34410882)
1. Evaluation of herb-drug interaction of ambrisentan with shikonin based on UPLC-MS/MS.
Lan T; Fang P; Ye X; Lan X; Xu RA
Pharm Biol; 2021 Dec; 59(1):1133-1138. PubMed ID: 34410882
[TBL] [Abstract][Full Text] [Related]
2. The effect of shikonin on the metabolism of lapatinib in vitro, and in vivo.
Hu Y; Xie S; Xia H; Chen J; Yang Y; Zhan R
Toxicol Appl Pharmacol; 2024 Jan; 482():116797. PubMed ID: 38160892
[TBL] [Abstract][Full Text] [Related]
3. LC-ESI-MS/MS method for quantification of ambrisentan in plasma and application to rat pharmacokinetic study.
Nirogi R; Kandikere V; Komarneni P; Aleti R; Padala N; Kalaikadhiban I
Biomed Chromatogr; 2012 Oct; 26(10):1150-6. PubMed ID: 22222607
[TBL] [Abstract][Full Text] [Related]
4. High-performance liquid chromatography tandem mass spectrometry method for quantification of endothelin receptor antagonist drug, ambrisentan, in human plasma and its application in a pharmacokinetic study.
Lukram OK; Sharma R
Biomed Chromatogr; 2014 Aug; 28(8):1147-55. PubMed ID: 24616031
[TBL] [Abstract][Full Text] [Related]
5. Metabolite characterization of ambrisentan, in in vitro and in vivo matrices by UHPLC/QTOF/MS/MS: Detection of glutathione conjugate of epoxide metabolite evidenced by in vitro GSH trapping assay.
Johnsi Rani P; Vishnuvardhan C; Nimbalkar RD; Garg P; Satheeshkumar N
J Pharm Biomed Anal; 2018 Jun; 155():320-328. PubMed ID: 29684813
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous quantification of ambrisentan, macitentan and sitaxentan in human plasma using UPLC-MS/MS.
van de Velde D; Bahmany S; Hitzerd E; van Domburg B; Versmissen J; Danser AHJ; Koch BCP
Biomed Chromatogr; 2020 Mar; 34(3):e4787. PubMed ID: 31875652
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence and Tolerability of Ambrisentan: A Pharmacokinetic Study in Mexican Healthy Male Subjects.
Cárdenas KPC; Velázquez JER; Escobar JJO; Chirinos J; Pendela M
Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):611-618. PubMed ID: 32472357
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study.
Chen M; Song W; Wang S; Chen Q; Pan P; Xu T; Hu G; Zheng Z
J Chromatogr Sci; 2016 Aug; 54(7):1159-65. PubMed ID: 27240565
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers.
Spence R; Mandagere A; Dufton C; Venitz J
J Clin Pharmacol; 2008 Dec; 48(12):1451-9. PubMed ID: 18832294
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Herb-Drug Interactions of Plumbagin and Tazemetostat in Rats by UPLC-MS/MS.
Li H; Wang YJ; Geng XN; Kang YR; Wang YL; Qiu XJ
Drug Des Devel Ther; 2022; 16():3385-3394. PubMed ID: 36199632
[TBL] [Abstract][Full Text] [Related]
11. Bionalytical validation study for the determination of unbound ambrisentan in human plasma using rapid equilibrium dialysis followed by ultra performance liquid chromatography coupled to mass spectrometry.
Garcia-Martínez S; Rico E; Casal E; Grisaleña A; Alcaraz E; King N; Leal N; Navarro I; Campanero MÁ
J Pharm Biomed Anal; 2018 Feb; 150():427-435. PubMed ID: 29289894
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.
Walker G; Mandagere A; Dufton C; Venitz J
Br J Clin Pharmacol; 2009 May; 67(5):527-34. PubMed ID: 19552747
[TBL] [Abstract][Full Text] [Related]
13. Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1.
Markert C; Hellwig R; Burhenne J; Hoffmann MM; Weiss J; Mikus G; Haefeli WE
Eur J Clin Pharmacol; 2013 Oct; 69(10):1785-93. PubMed ID: 23748747
[TBL] [Abstract][Full Text] [Related]
14. In vivo and in vitro metabolism and pharmacokinetics of cholinesterase inhibitor deoxyvasicine from aerial parts of Peganum harmala Linn in rats via UPLC-ESI-QTOF-MS and UPLC-ESI-MS/MS.
Deng G; Liu W; Ma C; Rong X; Zhang Y; Wang Y; Wu C; Cao N; Ding W; Guan H; Cheng X; Wang C
J Ethnopharmacol; 2019 May; 236():288-301. PubMed ID: 30872168
[TBL] [Abstract][Full Text] [Related]
15. The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype.
Markert C; Kastner IM; Hellwig R; Kalafut P; Schweizer Y; Hoffmann MM; Burhenne J; Weiss J; Mikus G; Haefeli WE
Basic Clin Pharmacol Toxicol; 2015 May; 116(5):423-8. PubMed ID: 25286744
[TBL] [Abstract][Full Text] [Related]
16. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study.
Harrison B; Magee MH; Mandagere A; Walker G; Dufton C; Henderson LS; Boinpally R
Clin Drug Investig; 2010; 30(12):875-885. PubMed ID: 20923245
[TBL] [Abstract][Full Text] [Related]
17. UPLC-MS/MS for the Herb-Drug Interactions of Xiao-Ai-Ping Injection on Enasidenib in Rats Based on Pharmacokinetics.
Wang BW; Qiu CZ; Tang CQ; Zhang JH; Zhang Y; Du QG; Feng Y; Qiu XJ
Biomed Res Int; 2021; 2021():6636266. PubMed ID: 33688498
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous determination of bioactive components of Radix Angelicae Sinensis-Radix Paeoniae Alba herb couple in rat plasma and tissues by UPLC-MS/MS and its application to pharmacokinetics and tissue distribution.
Luo N; Li Z; Qian D; Qian Y; Guo J; Duan JA; Zhu M
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 963():29-39. PubMed ID: 24927419
[TBL] [Abstract][Full Text] [Related]
19. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.
Spence R; Mandagere A; Harrison B; Dufton C; Boinpally R
J Pharm Sci; 2009 Dec; 98(12):4962-74. PubMed ID: 19455620
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC-MS/MS assay.
Zhang Y; Liu YN; Xie S; Xu X; Xu RA
Pharm Biol; 2022 Dec; 60(1):621-626. PubMed ID: 35289238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
